Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)

Diabetologia

Volumn 59, Issue 2, 2016, Pages 299-306

  Livingstone, Shona J ^a   Looker, Helen C ^a   Akbar, Tahira ^a   Betteridge, D John ^b   Durrington, Paul N ^c   Hitman, Graham A ^d   Neil, H Andrew W ^e   Fuller, John H ^f   Colhoun, Helen M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Atorvastatin; Cardiovascular disease; Glycaemia; HbA1c

Indexed keywords

ATORVASTATIN; GLUCOSE; HEMOGLOBIN A1C; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SECONDARY ANALYSIS; SEX DIFFERENCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; IRELAND; METABOLISM; MIDDLE AGED; PATHOLOGY; UNITED KINGDOM;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IRELAND; MALE; MIDDLE AGED; UNITED KINGDOM;

EID: 84953371524     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3802-6     Document Type: Article

References (18)

1. Armitage J, Baigent C, Collins R (2014) Misrepresentation of statin safety evidence. Lancet 384:1263–1264
2. Godlee F (2014) Statins and the BMJ. BMJ 349:g5038
3. Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207
4. Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735–742
5. Swerdlow DI, Preiss D, Kuchenbaecker KB et al (2014) HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 385:351–361
6. Culver AL, Ockene IS, Balasubramanian R et al (2012) Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med 172:144–152
7. U.S. Food and Drug Administration (2012) FDA Drug safety communication: important safety label changes to cholesterol-lowering statin drugs. Available from http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm, accessed 6 October 2015
8. Cederberg H, Stancakova A, Yaluri N, Modi S, Kuusisto J, Laakso M (2015) Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 58:1109–1117
9. Erqou S, Lee CC, Adler AI (2014) Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia 57:2444–2452
10. Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696
11. World Health Organization (1985) Diabetes mellitus. Report of a WHO Study Group. (Technical Report Series 727). World Health Organization, Geneva
12. Fine J, Gray R (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509
13. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23:469–480
14. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK (2010) Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 55:1209–1216
15. Thongtang N, Ai M, Otokozawa S et al (2011) Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol 107:387–392
16. Waters DD, Ho JE, DeMicco DA et al (2011) Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. Am J Cardiol 57:1535–1545
17. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ (2012) Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380:565–571
18. Preiss D, Seshasai SR, Welsh P et al (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305:2556–2564